Genitourinary Cancers Symposium Media Resource Center

Embargo Policy

The embargo on all abstracts part of the 2015 Genitourinary Cancers Symposium will lift at 5:00 PM ET on Monday, February 23, 2015. An embargoed presscast (virtual press briefing held via teleconference and webinar) will be held at 12:00 noon ET on February 23 for credentialed media.

How to Obtain Media Credentials and/or Register to Attend the Symposium in Orlando

Media registration for the 2015 Genitourinary Cancers Symposium will open on November 6, 2014.

*If you attended the 2014 ASCO Annual Meeting or covered the meeting remotely, you have already been credentialed by ASCO and will have access to the embargoed meeting information and the February 23 Presscast. You only have to register if you want to attend the Symposium in Orlando.

Access Embargoed Information

Embargoed meeting information will be made available to credentialed media through ASCO's Media Headquarters.Once your media credentials are approved, you will receive email notifications when embargoed information has been posted.

Press Releases

2015 Symposium Highlights Notable Research Advances in Genitourinary CancersOrlando – Six studies exploring key issues in the treatment of genitourinary cancers will be presented at the 2015 Genitourinary Cancers Symposium, taking place February 26-28 in Orlando. These notable abstracts investigate several approaches to prostate cancer – short-term ADT, brachytherapy, cabozantinib, docetaxel, and statins – as well as the association between obesity and fatal kidney cancer. Read the full release.

Androgen Receptor Abnormality May Not Be Associated With Primary Resistance to Taxane ChemotherapyALEXANDRIA, Va. – Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Read the full release.

Early Evidence of Increase in Higher-Risk Prostate Cancers From 2011-2013ALEXANDRIA, Va. – An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 finds a notable increase in higher-risk cases of the disease between 2011 and 2013. The retrospective analysis of patient data found the proportion of men diagnosed with intermediate- and high-risk disease increased by nearly 6 percent in those years. Read the full release.

Men Who Have Had Testicular Cancer Are More Likely to Develop Prostate Cancer, Although Overall Risk of Developing Aggressive Disease is LowALEXANDRIA, Va. – A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6 percent) than among those without a history of testicular cancer (2.8 percent). Read the full release.

Active Surveillance of Intermediate-Risk Prostate Cancer Associated With Decreased SurvivalALEXANDRIA, Va. – An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Read the full release.

Adjuvant Sorafenib and Sunitinib Do Not Improve Outcomes in Locally Advanced Kidney CancerALEXANDRIA, Va. – Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. Read the full release.

2015 Genitourinary Cancers Symposium Press Program to Highlight New Insights for Development and Management of Prostate and Kidney CancersALEXANDRIA, Va. – Co-sponsors of the 2015 Genitourinary Cancers Symposium announced today five abstracts that will be featured in the meeting’s official press program. Read the full release.

View the February 23 Press Briefing

The February 23 press briefing recording is available in ASCO's Video Gallery.